Decrease of the okt8 positive t cell subset in polymyalgia rheumatica

Benlahrache, Charif; P, Segond; Auquier, L; Bouvet, Jean‐Pierre

doi:10.1002/art.1780261209

Cited by 26 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus monitoring of levels of CD8+ cells may prove useful in the regular follow up of patients with PMR/GCA.It is interesting that despite the severe decrease in CD8+ cell numbers there are no manifestations of decreased suppressor activity. Serum immunoglobulins are normal, and the paucity of autoantibodies (except antibodies to intermediate filaments) suggests that there is no B cell overactivity.3 4 One study of concanavalin A inducible suppressor function in PMR/GCA reported it to be normal 6. …”

mentioning

confidence: 99%

Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.

Dasgupta

Duke

Timms

et al. 1989

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

SUMMARY A prospective study of 33 patients with polymyalgia rheumatica/giant cell arteritis (PMR/GCA) was undertaken, firstly, to monitor sequentially peripheral blood CD8+ lymphocyte levels and, secondly, to assess the expression of activation markers on T lymphocyte subsets. The results indicated that there was a significant decrease in absolute numbers and relative percentages of CD8+ T lymphocytes, which returned to normal ranges after approximately 24 months' treatment, and that there was an increased percentage of CD8+ lymphocytes in PMR/GCA which express HLA class II antigens. We undertook a prospective study of patients with PMR/GCA, firstly, to monitor sequentially peripheral blood CD8+ lymphocyte levels and, secondly, to assess the expression of activation markers (HLA class II antigens and interleukin 2 receptor) on T lymphocyte subsets. Our results indicate that there is a profound decrease in absolute numbers of CD8+ T lymphocytes, which return to the normal range after approximately 24 months' treatment and that most CD8+ lymphocytes express class II antigens. Patients and methods PATIENTS AND CONTROLSThirty three patients were investigated. Blood samples were taken sequentially from the onset of disease (and before treatment with corticosteroids) and subsequently every three months up to 24 months. The diagnosis of polymyalgia rheumatica was based on myalgias involving shoulder and pelvic girdle muscle together with morning stiffness and an acute phase reaction (raised C reactive protein and erythrocyte sedimentation rate). Patients with giant cell arteritis were included after a positive temporal artery biopsy. All patients showed rapid and lasting remission of symptoms with corticosteroid treatment

show abstract

mentioning

confidence: 99%

Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.

Dasgupta

Duke

Timms

et al. 1989

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

show abstract

“…However, during that period many studies did not differentiate between GCA and polymyalgia rheumatica (PMR), a rheumatic disease that often overlaps with GCA. Nevertheless, some studies found that CD8+ T cells were decreased in these patients ( 65 – 67 ), but it is highly likely that these studies were confounded by glucocorticoid treatment ( 68 – 72 ). It was not until recently that the possible role of CD8+ T cells gained more interest ( 34 ), as CD8+ T cells were detected at the site of inflammation in GCA-affected lesions.…”

Section: Pathogenesis Of Gcamentioning

confidence: 99%

CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?

et al. 2021

View full text Add to dashboard Cite

Vasculitis refers to inflammation of blood vessels and can cause a variety of serious complications depending on which vessels are affected. Two different forms of vasculitis are Giant Cell Arteritis (GCA) and Granulomatosis with Polyangiitis (GPA). GCA is the most common form of vasculitis in adults affecting the large arteries and can lead to visual impairment and development of aneurysms. GPA affects small- and medium-sized blood vessels predominantly in the lungs and kidneys resulting in organ failure. Both diseases can potentially be fatal. Although the pathogenesis of GCA and GPA are incompletely understood, a prominent role for CD4+ T cells has been implicated in both diseases. More recently, the role of CD8+ T cells has gained renewed interest. CD8+ T cells are important players in the adaptive immune response against intracellular microorganisms. After a general introduction on the different forms of vasculitis and their association with infections and CD8+ T cells, we review the current knowledge on CD8+ T-cell involvement in the immunopathogenesis of GCA and GPA focusing on phenotypic and functional features of circulating and lesional CD8+ T cells. Furthermore, we discuss to which extent aging is associated with CD8+ T-cell phenotype and function in GCA and GPA.

show abstract

“…Several investigators have reported a selective depletion of circulating T cells of the CD8 cytotoxic/suppressor phenotype 94 , 95 . These cells are also absent from the lesions in the arterial wall 84 .…”

Section: Etiologymentioning

confidence: 99%

Progress in Gerontology: Polymyalgia Rheumatica and Temporal Arteritis

Goodwin¹

1992

J American Geriatrics Society

View full text Add to dashboard Cite

Decrease of the okt8 positive t cell subset in polymyalgia rheumatica

Cited by 26 publications

References 29 publications

Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.

Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.

CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?

Progress in Gerontology: Polymyalgia Rheumatica and Temporal Arteritis

Contact Info

Product

Resources

About